Skip to content
ContentLora

    Tip: press / anywhere to search.

    product

    Asundexian (Sunharbo)

    Also known as Sunharbo

    Asundexian, sold as Sunharbo, is the first factor XIa inhibitor approved by the FDA, on 9 November 2026, for use with antiplatelet drugs to reduce the risk of stroke after a recent mild-to-moderate non-cardioembolic ischaemic stroke or high-risk TIA.[1] In the 12,327-patient OCEANIC-STROKE trial the FDA said it cut the risk of ischaemic stroke by 26% compared with placebo; the overall rate of major bleeding was similar, but higher in people over 75 and in the first 90 days.[2][3][4] It is not approved for stroke prevention in atrial fibrillation, where an earlier trial found it inferior to apixaban.[5][6]

    Editor reviewedStrict sourcingUpdated Wiki10 claims · 100% primaryHealth and medicine
    Key facts

    Asundexian is a blood thinner that blocks factor XIa, a protein in the clotting cascade. On 9 November 2026 the FDA approved it as Sunharbo, the first factor XIa inhibitor. It is approved for use with antiplatelet therapy to reduce the risk of stroke in adults after a recent mild-to-moderate non-cardioembolic ischaemic stroke or a high-risk transient ischaemic attack (TIA).[1] The approval went to Bayer HealthCare Pharmaceuticals, after the FDA had given the drug Fast Track and Priority Review designations.[7]

    This page is not medical advice. Decisions about blood thinners should be made with a doctor.

    The OCEANIC-STROKE trial

    The approval rests on OCEANIC-STROKE, a randomized, double-blind, placebo-controlled phase 3 trial of 12,327 adults. Participants started asundexian or placebo within 72 hours of a non-cardioembolic ischaemic stroke or high-risk TIA, and both groups also received antiplatelet therapy.[2] The FDA said asundexian reduced the risk of ischaemic stroke by 26% compared with placebo over a median of 14.2 months of treatment.[3] A 2026 review reported that the benefit was consistent across stroke subtypes, without an excess of major bleeding or bleeding in the brain.[8]

    Safety

    The FDA said the overall rate of major bleeding was similar with asundexian and placebo. It was higher with asundexian in people older than 75 and during the first 90 days of treatment, and gastrointestinal bleeding was more common with asundexian.[4] Diarrhoea was the most frequently reported side effect, and the drug is not recommended for people with moderate or severe liver impairment.[9]

    Atrial fibrillation

    Asundexian is not approved for stroke prevention in people with atrial fibrillation.[5] In the earlier OCEANIC-AF trial it was inferior to apixaban for that use. A 2026 review attributed the result to the dose, the comparator and the setting.[6]

    Context

    Asundexian is the first approved member of a new class of blood thinners, explained in factor XIa blood thinners explained.[1] Reviewers note that people who have had this kind of stroke remain at substantial risk of another despite antiplatelet drugs, and that older anticoagulants carry too much bleeding risk for them.[10] For the condition itself, see stroke explained.

    Factor XIa blood thinners explained

    What factor XIa inhibitors are, why they might prevent clots with less bleeding, the first FDA approval in 2026 and the trials that failed.

    More in Health & medicine

    Questions readers ask

    What is asundexian?

    A blood thinner that blocks factor XIa, a clotting protein. Sold as Sunharbo by Bayer, it was the first drug of its kind approved by the FDA, on 9 November 2026.[1][7]

    Who is it approved for?

    Adults who have had a recent mild-to-moderate non-cardioembolic ischaemic stroke (one caused by a clot that did not come from the heart) or a high-risk transient ischaemic attack. It is taken together with antiplatelet therapy.[1]

    How well did it work?

    In OCEANIC-STROKE, the FDA said it reduced the risk of ischaemic stroke by 26% compared with placebo over a median of 14.2 months.[3]

    Does it raise bleeding risk?

    The overall rate of major bleeding was similar to placebo, but it was higher in people older than 75 and in the first 90 days, and gastrointestinal bleeding was more common.[4]

    Can people with atrial fibrillation use it?

    It is not approved for stroke prevention in atrial fibrillation. In the earlier OCEANIC-AF trial it was inferior to apixaban in that setting.[5][6]

    Sources

    · 10 claims from 3 publishers

    Each numbered claim is a statement we checked against the sources listed with it. Tap a number in the text to see its sources in place.

    1. [1]

      On 9 November 2026 the FDA approved Sunharbo (asundexian), the first factor XIa inhibitor, for use with antiplatelet therapy to reduce the risk of stroke in adults after a recent mild-to-moderate non-cardioembolic ischaemic stroke or a high-risk transient ischaemic attack (TIA). confirmedas of 2026-11-09

    2. [2]

      The approval was based on OCEANIC-STROKE, a randomized, double-blind, placebo-controlled phase 3 trial of 12,327 adults who started asundexian or placebo within 72 hours of a non-cardioembolic ischaemic stroke or high-risk TIA; both groups also received antiplatelet therapy. confirmedas of 2026-11-09

    3. [3]

      The FDA said asundexian reduced the risk of ischaemic stroke by 26% compared with placebo over a median treatment period of 14.2 months in OCEANIC-STROKE. confirmedas of 2026-11-09

    4. [4]

      According to the FDA, the overall rate of major bleeding was similar with asundexian and placebo but was higher with asundexian in patients older than 75 and during the first 90 days, and gastrointestinal bleeding was more common with asundexian. confirmedas of 2026-11-09

    5. [5]

      Asundexian is not approved for stroke prevention in people with atrial fibrillation. confirmedas of 2026-11-09

    6. [6]

      In the earlier OCEANIC-AF trial, asundexian was inferior to apixaban for stroke prevention in atrial fibrillation; a 2026 review attributed this to the dose, the comparator and the setting. confirmedas of 2026-10-27

    7. [7]

      The FDA granted the approval to Bayer HealthCare Pharmaceuticals, after giving asundexian Fast Track and Priority Review designations. confirmedas of 2026-11-09

    8. [8]

      A 2026 review of OCEANIC-STROKE reported that asundexian added to single or dual antiplatelet therapy reduced recurrent ischaemic stroke consistently across stroke subtypes, without an excess of major bleeding or intracranial haemorrhage. confirmedas of 2026-10-27

    9. [9]

      The FDA said diarrhoea was the most frequently reported adverse reaction, occurring in 3% or more of asundexian-treated patients, and that asundexian is not recommended in people with moderate or severe liver impairment. confirmedas of 2026-11-09

    10. [10]

      Reviewers note that people with non-cardioembolic ischaemic stroke face a substantial risk of another stroke despite antiplatelet drugs, that conventional anticoagulants carry too high a bleeding risk for them, and that factor XIa inhibition promises anticoagulant effect while sparing normal blood clotting (haemostasis). confirmedas of 2026-10-27

    Revision history (1)
    1. Page created.

    Created Nov 14, 2026. Last reviewed by an editor on Nov 15, 2026. Next scheduled review: May 14, 2027.

    Cite this page

    "Asundexian (Sunharbo)." ContentLora, updated Nov 14, 2026. https://contentlora.com/wiki/asundexian

    Spotted an error? Suggest a correction or emailcorrections@contentlora.com.